BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36468955)

  • 1. Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy.
    Perche P; Purvis C; Pichardo R
    J Drugs Dermatol; 2022 Dec; 21(12):1366-1368. PubMed ID: 36468955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
    Brown L; Skopit S
    J Drugs Dermatol; 2018 Aug; 17(8):914-917. PubMed ID: 30124734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral tofacitinib for the treatment of alopecia areata in pediatric patients.
    Kibbie J; Kines K; Norris D; Dunnick CA
    Pediatr Dermatol; 2022 Jan; 39(1):31-34. PubMed ID: 34779041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
    Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
    JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
    Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
    Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: A prospective, open-label, single-center study in Asian Arab population.
    Husein-ElAhmed H; Abdulla N; Al-Obaidli A; Ali-Alam M; Steinhoff M
    Dermatol Ther; 2022 Dec; 35(12):e15871. PubMed ID: 36177791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
    Cheng MW; Kehl A; Worswick S; Goh C
    J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
    Liu LY; Craiglow BG; Dai F; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
    Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
    J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib in paediatric dermatoses: a narrative review.
    Agarwal I; Panda M; Das A
    Clin Exp Dermatol; 2022 Jul; 47(7):1256-1264. PubMed ID: 35279865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
    Craiglow BG; Liu LY; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
    Benton S; Farah R; Freese R; Hordinsky M
    Dermatol Ther; 2022 Apr; 35(4):e15310. PubMed ID: 34997820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Alopecia areata with good response to tofacitinib].
    Maksimow A; Stintzing D; Wohlrab J
    Hautarzt; 2021 Jun; 72(6):525-527. PubMed ID: 33044559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib as a treatment of alopecia areata in adolescents.
    Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R
    Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitiligo and alopecia areata: apples and oranges?
    Harris JE
    Exp Dermatol; 2013 Dec; 22(12):785-9. PubMed ID: 24131336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
    Yu DA; Kim YE; Kwon O; Park H
    Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges of securing insurance approval for oral tofacitinib for the treatment of alopecia areata: a multi-institution retrospective review.
    Desai S; Lo K; Nambudiri VE; Villa-Ruiz C; LaChance A; Vleugels RA
    Arch Dermatol Res; 2022 Jul; 314(5):487-489. PubMed ID: 33403573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colocalization of vitiligo and alopecia areata presenting as poliosis.
    Walker A; Mesinkovska NA; Boncher J; Tamburro J; Bergfeld WF
    J Cutan Pathol; 2015 Feb; 42(2):150-4. PubMed ID: 25388912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.